Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...
Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...
The dyad model fosters collaboration between academic specialists and community oncologists, ensuring seamless patient care ...
Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...
Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
Genetic and metabolic differences may increase aggressive early breast cancer risk in Latin American women with obesity, ...
With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care ...
With the debut of TrumpRx.gov and other moves, the administration is steering the nation toward a market-driven, “America ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results